New and updated clinical data presented by biopharma firms at the American Society of Hematology annual meeting and exposition, including: Amgen, Beigene, Novartis, Pharming.

New and updated clinical data presented by biopharma firms at the American Society of Hematology annual meeting and exposition, including: Alx, Avencell, Atara, Cellectis, Coimmune, Corvus, Disc, Elixirgen, Galapagos, Genentech, Glycomimetics, Gracell, GSK, Harpoon, Imago, Immunogen, In8bio, Incyte, Innate, Innovent, Janssen, Junshi, JW, Karyopharm, Keros, Kite, Kura, Lava, Loxo, Maat, Magenta, Mendus, Nektar, Nurix, Oncternal, Orca, Orchard, Oryzon, Pfizer, Prothena, Regeneron, Roche, Rocket, Ryvu, Seagen, Sellas, Starpharma, Sumitomo, Sutro, Syndax, Syntrix, Syros, Taiho, Tessa, Treadwell, Vincerx, X4, Xencor.

After gaining U.S. FDA priority approval for the first gene therapy to treat hemophilia B, CSL Ltd. reported long-term data from the pivotal HOPE-B trial that showed a single infusion of Hemgenix (etranacogene dezaparvovec-drlb) generated elevated and sustained mean factor IX levels and reduced the rate of annual bleeding.